
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Under the agreement, which foresees US$425m in milestones plus royalities on future sales for 3B Pharmaceuticals GmbH (3BP), Basel-based pharma...

Ariceum Therapeutics extends Series A to €47.75m
The Series A financing was co-led by new investors Andera Partners and Earlybird Venture Capital. Existing investor Pureos Bioventures doubled its...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Algal enzyme synthesizes gasoline building blocks
Deciphering the mechanism of the photoenzyme Fatty acid photodecarboxylase (FAP), a research team co-headed by Frederic Beisson from University...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...